The estimated Net Worth of Geoffrey O Brien is at least $1.72 Milion dollars as of 19 May 2021. Mr. Brien owns over 43,318 units of Medicinova Inc stock worth over $94,703 and over the last 11 years he sold MNOV stock worth over $0. In addition, he makes $1,628,480 as Vice President at Medicinova Inc.
Sign up
Mr. brien MNOV stock SEC Form 4 insiders trading
Geoffrey has made over 2 trades of the Medicinova Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 43,318 units of MNOV stock worth $109,161 on 19 May 2021.
The largest trade he's ever made was exercising 43,318 units of Medicinova Inc stock on 19 May 2021 worth over $109,161. On average, Geoffrey trades about 3,108 units every 119 days since 2013. As of 19 May 2021 he still owns at least 48,318 units of Medicinova Inc stock.
You can see the complete history of Mr. Brien stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Geoffrey O'brien biography
Geoffrey G. O'brien J.D. serves as Vice President of the Company. Mr. O'Brien previously served as our Senior Director, Business Development and Strategic Planning since 2012, and as Director, Business Development since 2009. Prior to joining us, Mr. O’Brien was an equity research analyst covering pharmaceutical and biotechnology companies at several investment banks including UBS Securities, Nomura Securities, and Punk Ziegel, working at the Vice President level from 2004 to 2008. He was also a healthcare investment banker at Donaldson, Lufkin & Jenrette/Credit Suisse First Boston. Prior to graduate school, he worked on the successful development of a biotechnology product at The Liposome Company. Mr. O’Brien received a B.S. in chemistry, cum laude, from the University of Delaware and completed his J.D. and M.B.A. simultaneously at Vanderbilt Law School and Owen Graduate School of Management at Vanderbilt University.
What is the salary of Geoffrey brien?
As the Vice President of Medicinova Inc, the total compensation of Geoffrey brien at Medicinova Inc is $1,628,480. There are 2 executives at Medicinova Inc getting paid more, with Yuichi Iwaki having the highest compensation of $3,761,890.
How old is Geoffrey brien?
Geoffrey brien is 51, he's been the Vice President of Medicinova Inc since 2013. There are 9 older and 1 younger executives at Medicinova Inc. The oldest executive at Medicinova Inc is Dr. Yuichi Iwaki M.D., Ph.D., 71, who is the Co-Founder, Pres, CEO & Exec. Director.
What's Geoffrey brien's mailing address?
Geoffrey's mailing address filed with the SEC is C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA, CA, 92037.
Insiders trading at Medicinova Inc
Over the last 18 years, insiders at Medicinova Inc have traded over $200,908 worth of Medicinova Inc stock and bought 459,744 units worth $1,581,779 . The most active insiders traders include Jeff Himawan, Masatsune Okajima oraz Yuichi Iwaki. On average, Medicinova Inc executives and independent directors trade stock every 95 days with the average trade being worth of $74,094. The most recent stock trade was executed by Hideki Nagao on 28 November 2022, trading 6,754 units of MNOV stock currently worth $15,197.
What does Medicinova Inc's logo look like?
Complete history of Mr. Brien stock trades at Medicinova Inc
Medicinova Inc executives and stock owners
Medicinova Inc executives and other stock owners filed with the SEC include:
-
Yuichi Iwaki,
President, Chief Executive Officer, Director -
Kazuko Matsuda,
Chief Medical Officer, Director -
Geoffrey O'brien,
Vice President -
Dr. Yuichi Iwaki M.D., Ph.D.,
Co-Founder, Pres, CEO & Exec. Director -
Dr. Kazuko Matsuda M.D., M.P.H., MPH, Ph.D.,
Chief Medical Officer & Director -
Hideki Nagao,
Independent Director -
Carolyn Beaver,
Director -
Edward Stepanow,
Chief Financial Officer -
Jeffrey Himawan,
Independent Chairman of the Board -
John O'Neil CPA,
Controller -
Dr. David H. Crean Ph.D.,
Chief Bus. Officer -
Dr. Federico Gaeta Ph.D.,
Chief Scientific Officer -
Douglas G Paulin CPA, CPA,
Chief Financial Officer -
Yutaka Kobayashi,
Director -
Yoshio Ishizaka,
Director -
Masatsune Okajima,
VP and Head of Japanese Office -
Federico C.A. Gaeta,
Chief Scientific Officer -
Tatsuo Izumi,
Director -
Den Boom Esther Van,
Chief Financial Officer -
Jeff Himawan,
Director -
John K A Prendergast,
Director -
Hiroaki Shigeta,
Director -
Kirk William Johnson,
Chief Scientific Officer -
Arlene Morris,
Director -
Michael Denis Coffee,
Chief Business Officer -
David D O'toole,
Director -
Alan W Dunton,
Director -
Shintaro Asako,
VP and Chief Financial Officer -
Richard E Sr Gammans,
Chief Development Officer -
Daniel Vapnek,
Director -
Kenneth W Locke,
Chief Scientific Officer -
Michael E Kalafer,
Chief Medical Officer -
Nicole Lemerond,
Director